Mass General Brigham
Boston, Massachusetts, 02120, United States
NCT Number: NCT06347172
The objectives of this study are to demonstrate the feasibility of implementing a deprescribing nudge intervention using pragmatic methods, confirm that outcomes can be feasibly measured and evaluated at scale in a subsequent embedded pragmatic clinical trial (ePCT), and explore representativeness of persons living with dementia and care partners identified.
Looking for future studies?
Notify Me65 year and older
All sexes
Interventional
Not applicable
Boston, Massachusetts, 02120, United States
The PCP nudge will consist of: a 'pre-commitment' EHR nudge triggered when a PCP opens a patient encounter (i.e., prompt to first have a discussion and then later deprescribe) and a brief message within the in-basket prior to upcoming visits including information about their patient. The patient living with dementia (PLWD)/care partner nudge will include an electronic message delivered prior to upcoming visits (in their primary language recorded in the EHR) that includes a recommendation for the PLWD (and care partner, if available) to discuss medications with the PCP at the visit.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Primary care providers will be the primary unit of identification and randomization.
Primary care providers inclusion criteria:
Eligible patients will be identified through this providers within the health care system.
Patient inclusion criteria:
PCPs will receive an enhanced EHR alert (nudge) that triggers when a PCP opens an encounter for an eligible patient living with dementia (PLWD). The nudge will provide information about the risks of continued medication use as well as tips and tools to help providers discuss medication discontinuation with patients and care partners. Additionally, the providers will receive a brief message in their in-basket 10 days before the patient's appointment as a reminder.
Eligible PLWD of a randomized PCP will receive the nudge intervention which includes a brief recommendation for the PLWD (and care partner, if available) via the linked patient portal prior to upcoming visits (unless explicitly opted out by the PCP) to discuss medications with the PCP at the visit and link to a general handout about medications, unless explicitly opted out by the PCP. For PLWD without a portal account, the handout will be sent to their mailing address recorded in the EHR.
Time frame: On or before the primary care provider visit, up to 10 days
This is the primary progression criteria for the study, measured on the patient level. This is measured as a composite of the number of eligible PCPs or their PLWD/care partners who view or click on information on or before the primary care provider visit, up to 10 days
Time frame: On the primary care provider visit date
Number of patients who had provider EHR alerts that fired as intended, measured among patients who had a completed target visit (n=99) within EHR data.
Time frame: Within 60 days on or after the primary care provider visit
Discontinuation or prescribed reduction in dose of at least one high-risk medication of interest within 60 days after the visit using data from the EHR system, measured on the patient-level as the number of patients who have medications discontinued or have a prescribed reduction.
Brigham and Women's Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05318976
Alzheimer Disease, Brain Diseases
Darlinghurst, New South Wales, Australia
View Trial DetailsNCT06366867
Aging, Alzheimer Disease
Edmonton, Canada
View Trial DetailsNCT05427448
Alzheimer Disease, Brain Diseases
Montpellier, Occitanie, France
View Trial DetailsNCT05159557
Alzheimer Disease, Brain Diseases
Berkeley, California, United States
View Trial Details